COAG vs SNY: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. COAG and SNY share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined COAG and SNY exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Hemab Therapeutics Holdings (NASDAQ: COAG) is a clinical-stage biotechnology company founded in 2020 with operations in Cambridge, Massachusetts and Denmark. It develops therapies for rare and underserved bleeding disorders. Its lead candidate, sutacimig (HMB-001), is a bispecific antibody in development as a prophylactic treatment for Glanzmann thrombasthenia (which has a Breakthrough Therapy Designation) and Factor VII deficiency, with additional programs targeting von Willebrand disease (HMB-002) and heavy menstrual bleeding (HMB-003). The company has roughly 59 employees and no approved products or meaningful product revenue.

Full COAG guide

Sanofi S.A. is one of the world's largest pharmaceutical companies, based in France and organized around biopharma (specialty care, general medicines) and vaccines. Its single most important product is Dupixent, an immunology drug co-developed with Regeneron that treats conditions like eczema, asthma, and COPD; Dupixent sales moved above the roughly four-billion-euro-per-quarter mark in Q1 2026 and grew more than 30% year over year, making it the engine of the company's revenue growth. Sanofi also runs a major vaccines business (including the RSV antibody Beyfortus and the newly acquired hepatitis-B vaccine Heplisav-B) and spun off its consumer-health arm, Opella (Allegra, Icy Hot, Dulcolax), in 2025 to focus purely on innovative medicines and vaccines.

Full SNY guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• COAG drivers: Sutacimig lead program; Pipeline breadth in rare bleeding disorders.
• SNY drivers: Dupixent as the growth engine; Pipeline and new launches.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: As a pre-revenue clinical-stage biotech, COAG carries substantial risk and its value depends on trial outcomes that are inherently binary. For SNY, the clearest risk is concentration in Dupixent: with one product carrying so much of the growth, its eventual loss of patent exclusivity later this decade is the central overhang, and the pipeline may or may not fully replace it.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick COAG if you believe its drivers more; SNY if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the COAG and SNY guides.

COAG. COAG has no meaningful product revenue and is valued on the expected future worth of its pipeline, not on earnings, so standard metrics like P/E do not apply. Its roughly $2.3 billion market cap sits against ongoing net losses of about $71 million, offset by a strong cash position funding operations into 2029. The stock has risen from an $18 IPO price toward $49, meaning the market already prices in meaningful clinical success.

SNY. Figures are approximate, drawn from public 2026 reporting, and tied to the asOf date; verify live numbers before acting. Sanofi reports in euros, so the dollar value of SNY and its dividend also depends on the euro-to-dollar exchange rate. As a defensive large-cap pharma, the stock tends to trade on pipeline news, Dupixent momentum, and the eventual patent-expiry timeline rather than on sharp cyclical swings.

Headline figures (approximate, JULY 2026): COAG shows market cap ~$2.3B, share price ~$49, product revenue (ttm) ~$0 (pre-commercial), net loss (trailing) ~-$71M; SNY shows company type Large-cap, diversified global pharmaceutical company (French, US-listed as an ADR on Nasdaq), market cap ~$107 billion (approximate; among the larger global pharma names), q1 2026 revenue ~10.5 billion euros, ahead of consensus (reported figures are in euros), q1 2026 business eps ~1.88 euros, up ~14% at constant exchange rates.

COAG and SNY are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined COAG and SNY exposure against your real portfolio. It is not an investment adviser.